Search

International audience; We report on high-resolution laser spectroscopy studies on Cf249–253 with spectral linewidths in the order of 100 MHz carried out at the RISIKO mass separator at Mainz University. In total three atomic ground-state transitions were investigated and the hyperfine parameters for the odd-A isotopes and isotope shift for all examined isotopes have been determined from the measured spectra. The isotope shift measurements allowed tracking of changes in mean-squared charge radii across the deformed nuclear shell closure at N=152, whereby shape discontinuities were not observed. Experimental hyperfine coupling constants of the atomic ground state were combined with relativistic many-body atomic calculations to extract the nuclear magnetic-dipole moment of Cf249 with improved precision to μI(249Cf)=−0.395(17)μN, whereas μI(251Cf)=−0.571(24)μN and μI(253Cf)=−0.731(35)μN were derived for the first time. Additionally, the spectroscopic quadrupole moments QS(249Cf)=6.27(33)eb and QS(253Cf)=5.53(51)eb were extracted.

Physical review / C 107(3), 034313 (2023). doi:10.1103/PhysRevC.107.034313, Published by Inst., Woodbury, NY

Terbium-149 is among the most interesting therapeutic nuclides for medical applications. It decays by emission of short-range α-particles (Eα = 3.967 MeV) with a half-life of 4.12 h. The goal of this study was to investigate the anticancer efficacy of a 149Tb-labeled DOTA-folate conjugate (cm09) using folate receptor (FR)-positive cancer cells in vitro and in tumor-bearing mice. 149Tb was produced at the ISOLDE facility at CERN. Radiolabeling of cm09 with purified 149Tb resulted in a specific activity of ~1.2 MBq/nmol. In vitro assays performed with 149Tb-cm09 revealed a reduced KB cell viability in a FR-specific and activity concentration-dependent manner. Tumor-bearing mice were injected with saline only (group A) or with 149Tb-cm09 (group B: 2.2 MBq; group C: 3.0 MBq). A significant tumor growth delay was found in treated animals resulting in an increased average survival time of mice which received 149Tb-cm09 (B: 30.5 d; C: 43 d) compared to untreated controls (A: 21 d). Analysis of blood parameters revealed no signs of acute toxicity to the kidneys or liver in treated mice over the time of investigation. These results demonstrated the potential of folate-based α-radionuclide therapy in tumor-bearing mice.

Terbium-149 is among the most interesting therapeutic nuclides for medical applications. It decays by emission of short-range α-particles (Eα = 3.967 MeV) with a half-life of 4.12 h. The goal of this study was to investigate the anticancer efficacy of a 149Tb-labeled DOTA-folate conjugate (cm09) using folate receptor (FR)-positive cancer cells in vitro and in tumor-bearing mice. 149Tb was produced at the ISOLDE facility at CERN. Radiolabeling of cm09 with purified 149Tb resulted in a specific activity of ~1.2 MBq/nmol. In vitro assays performed with 149Tb-cm09 revealed a reduced KB cell viability in a FR-specific and activity concentration-dependent manner. Tumor-bearing mice were injected with saline only (group A) or with 149Tb-cm09 (group B: 2.2 MBq; group C: 3.0 MBq). A significant tumor growth delay was found in treated animals resulting in an increased average survival time of mice which received 149Tb-cm09 (B: 30.5 d; C: 43 d) compared to untreated controls (A: 21 d). Analysis of blood parameters revealed no signs of acute toxicity to the kidneys or liver in treated mice over the time of investigation. These results demonstrated the potential of folate-based α-radionuclide therapy in tumor-bearing mice., Pharmaceuticals, 7 (3), ISSN:1424-8247